Advertisement

Drugs in R & D

, Volume 3, Issue 5, pp 331–336 | Cite as

Watanidipine

AE 0047, Calbren®, GJ 0956, Vatanidipine
Research Review Adis R&D Profile
  • 6 Downloads

Keywords

Essential Hypertension Nicardipine Nitrendipine Urinary Sodium Excretion Nilvadipine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hayashi K, Gohda M, Matzno S, Kubo Y, Kido H, et al. Possible mechanism of action of AE0047, a calcium antagonist, on triglyceride metabolism. Journal of Pharmacology and Experimental Therapeutics 282: 882–890, Aug 1997PubMedGoogle Scholar
  2. 2.
    Azuma J, Harada H, Kurimoto T, et al. Phase I study of GJ-0956, Ca antagonist. Rinsho Iyaku 13: 2121–2144, No. 9, 1997Google Scholar
  3. 3.
    Ogihara T, Higaki J, Aoki T, et al. Pharmacokinetic study of GJ-0956 (watanidipine hydrochloride) in elderly healthy people. Rinsho Iyaku 13: 2159–2167, No. 9, 1997Google Scholar
  4. 4.
    Kaku T, Suzuki S, Yano K, et al. Pharmacokinetic study of GJ-0956 (watanidipine hydrochloride) in patients with essential hypertension. Rinsho Iyaku 13: 2887–2905, No. 11, 1997Google Scholar
  5. 5.
    Takeda T, Iimura O, Abe K, et al. Efficacy and safety of GJ-0956 monotherapy in patients with essential hypertension: a late phase II study for evaluation of optimum dose. Rinsho Iyaku 13: 2213–2236, No. 9, 1997Google Scholar
  6. 6.
    Takeda T, Iimura O, Abe K, et al. Efficacy and safety of GJ-0956 in combination with diuretic or beta-blocker in patients with essential hypertension. Rinsho Iyaku 13: 2237–2264, No. 9, 1997Google Scholar
  7. 7.
    Takeda T, Saruta T, Abe K, et al. Antihypertensive effect, safety and usefulness of GJ-0956 in hypertensive patients with renal impairment. Rinsho Iyaku 13: 2429–2461, No. 9, 1997Google Scholar
  8. 8.
    Hayashi K, Imada T, Yamauchi T, Kido H, Shinyama H, et al. Possible mechanism for the anti-atherosclerotic action of the calcium channel blocker AE0047 in cholesterol-fed rabbits. Clinical & Experimental Pharmacology and Physiology 25: 17–25, Jan 1998CrossRefGoogle Scholar
  9. 9.
    Hayashi K, Uchida T, Kido H, Shinyama H, Watanabe M. Effects of AE0047 on renal haemodynamics and function in anaesthetized dogs. Clinical and Experimental Pharmacology and Physiology 20: 103–111, Feb 1993PubMedCrossRefGoogle Scholar
  10. 10.
    Ohta Y, Chikugo T, Suzuki T. Long term therapeutic effects of ACE inhibitor and calcium antagonists on hypertensive vascular lesions in M-SHRSP. Clinical and Experimental Pharmacology and Physiology (Suppl 1): 103, 1994Google Scholar
  11. 11.
    Hayashi K, Uchida T, Kido H, et al. Diuretic effect and antiproteinuric effect of the novel calcium channel blocker AE0047. Japanese Journal of Pharmacology 64 (Suppl 1): 256, 1994Google Scholar
  12. 12.
    Hayashi K, Kido H, Kubo Y, Uchida T, Watanabe M. Uricosuric action of calcium channel blocker AE0047 in rats. Japanese Journal of Pharmacology 67 (Suppl I): 318, 1995Google Scholar
  13. 13.
    Ohta Y, Chikugo T-A, Suzuki T. Long-term therapeutic effects of ACE inhibitor and calcium antagonists on hypertensive vascular lesions in M-SHRSP. Clinical & Experimental Pharmacology and Physiology 22 (Suppl 1): 321–322, Dec 1995CrossRefGoogle Scholar
  14. 14.
    Ohtsuka K, Tsukiyama H, Ono Y, et al. Hemodynamic effect of the novel dihydropyridine calcium antagonist GJ-0956 (watanidipine hydrochloride) in essential hypertension. Rinsho Iyaku 13: 2347–2354, No. 9, 1997Google Scholar
  15. 15.
    Shinyama H, Nagai H, Kawamura T, et al. Effects of long-term antihypertensive treatment with AE0047, a novel Ca antagonist, on cerebrovascular autoregulation and hypertrophy in spontaneously hypertensive rats. Japanese Journal of Pharmacology 58 (Suppl 1): 405, 1992Google Scholar
  16. 16.
    Yamanaga K, Ohtaki Y, Uchida T, et al. Effect of a novel calcium antagonist AE0047 on several models of cerebral ischemia. Drug Development Research 26: 173–181, No. 2, 1992CrossRefGoogle Scholar
  17. 17.
    Shinyama H, Kawamura T, Nagai H, et al. A possible application of AE0047, a novel Ca antagonist for treatment of stroke. Japanese Journal of Pharmacology 61 (Suppl I): 132P, 1993Google Scholar
  18. 18.
    Kawamura T, Shinyama H, Narita Y, et al. Protective effect of AE0047, a novel Ca antagonist, on incidence of stroke in stroke-prone spontaneously hypertensive rats. Japanese Journal of Pharmacology 61 (Suppl I): 209P, 1993Google Scholar
  19. 19.
    Okita M, Shinyama H, Kawamura T, et al. Ameliorative effect of AE0047, a calcium channel blocker, on memory impairment after transient cerebral ischemia in rats. Japanese Journal of Pharmacology 64 (Suppl 1): 353, 1994Google Scholar
  20. 20.
    Takeda T, Iimura O, Abe K, et al. Clinical evaluation of GJ-0956 on essential hypertension: a double-blind comparative studywith nitrendipine. Rinsho Iyaku 13: 2907–2950, No. 11, 1997Google Scholar

Copyright information

© Adis International Limited 2002

Personalised recommendations